Gheith Osama A, Nagib Ayman M, Halim Medhat A, Mahmoud Tarek, Nair Prasad, Abo-Atya Hasaneen, Shaker Mohamed, Mostafa Mohamed, Attia Hosam, Alotaibi Torki
The Nephrology Department, Hamed Al-Essa Organ Transplant Center, Sabah Area, Kuwait.
Iran J Kidney Dis. 2023 Jan;17(1):47-53.
Data regarding contrast-induced nephropathy (CIN) in kidney transplant (KT) recipients are scarce despite the distinct risk factors such as the use of immunosuppressive agents, sympathetic denervation, glomerular hyperfiltration, and high prevalence of the cardiovascular disease. This study aimed to determine the prevalence of CIN in KT recipients who received low-osmolality iodine-based contrast material (CM) for radiological assessment.
Between 2010 and 2020, 79 of the 3180 KT recipients followed at Hamed Al-Essa organ transplant center received low-osmolality iodine-based contrast for radiological assessment for various indications. Preventive measures including holding metformin, intravenous hydration, sodium bicarbonate and N-acetylcysteine were given before contrast administration. CIN was defined as an increase in serum creatinine of 25% from the baseline within 72 hours.
The enrolled patients were divided into two groups: those who developed CIN (n = 7) and those with no increase in serum creatinine level (n = 72). The mean age of the patients was 52.1 ± 12.3 years; 44 of them were males, and the cause of end-stage kidney disease was mostly diabetic nephropathy. The pre-transplant demographics were comparable between the two groups. Fortyseven cases received contrast for coronary angiography, and 32 received it for a CT scan. The graft function deteriorated in group 1, but no significant difference was found between the two groups at the end of the study.
CIN is not uncommon in KT recipients receiving CM, especially with ischemic heart disease. Risk stratification, optimizing hemodynamics, and avoiding potential nephrotoxins are essential before performing CM-enhanced studies in KT recipients. DOI: 10.52547/ijkd.7165.
尽管肾移植(KT)受者存在使用免疫抑制剂、交感神经去支配、肾小球高滤过以及心血管疾病高患病率等独特的危险因素,但关于对比剂肾病(CIN)的数据却很稀少。本研究旨在确定接受低渗性碘对比剂(CM)进行放射学评估的KT受者中CIN的患病率。
2010年至2020年期间,在哈米德·阿勒·埃萨器官移植中心随访的3180例KT受者中,有79例因各种适应症接受了低渗性碘对比剂进行放射学评估。在给予对比剂之前采取了包括停用二甲双胍、静脉补液、碳酸氢钠和N - 乙酰半胱氨酸在内的预防措施。CIN定义为血清肌酐在72小时内较基线水平升高25%。
纳入的患者分为两组:发生CIN的患者(n = 7)和血清肌酐水平未升高的患者(n = 72)。患者的平均年龄为52.1±12.3岁;其中44例为男性,终末期肾病的病因大多为糖尿病肾病。两组移植前的人口统计学特征具有可比性。47例接受了冠状动脉造影对比剂,32例接受了CT扫描对比剂。第1组的移植肾功能恶化,但研究结束时两组之间未发现显著差异。
在接受CM的KT受者中,CIN并不罕见,尤其是合并缺血性心脏病时。在对KT受者进行CM增强检查之前,风险分层、优化血流动力学以及避免潜在的肾毒素至关重要。DOI: 10.52547/ijkd.7165